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Turoctocog alfa is a B-domain-truncated recombinant factor VIII protein produced in a Chinese hamster
ovary (CHO) cell line. The aim of this study was to evaluate the virus clearance capacity and robustness of
the turoctocog alfa puriﬁcation process. Virus clearance evaluation studies were conducted utilising a
scaled-down version of the manufacturing process. Total virus clearance was evaluated using the eco-
tropic murine leukaemia virus (eMuLV) as a model for non-infectious retrovirus-like particles (RVLPs)
and certain enveloped viruses. Other viruses utilised included: infectious bovine rhinotracheitis (IBRV),
minute virus of mice (MVM), bovine enterovirus (BEV) and Reo-3 virus (Reo-3). Robust clearance of all
model viruses was demonstrated with either new or reused resins. Overall, virus reduction factors were:
>18.0 log10 (eMuLV); 11.0 log10 (MVM); >11.8 log10 (Reo-3; >5.0 log10 using nanoﬁltration); >15.3 log10
(BEV) and >12.7 log10 (IBRV). Taken together, these values demonstrate that the puriﬁcation process for
turoctocog alfa effectively removes a range of enveloped and non-enveloped viruses of different phys-
icochemical properties and sizes.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Coagulation factor products are the primary therapy for patients
with haemophilia and factor VIII (FVIII) replacement is the treat-
ment of choice for patients with haemophilia A [1]. Historically,
clotting factor concentrates have been sourced from human blood;
however, such products may transmit blood-borne infections [2].
The transmission of pathogens has had profound and far-reaching
effects for patients with haemophilia, including infection by hep-
atitis C virus (HCV) [3,4], hepatitis B virus (HBV) [3] and human
immunodeﬁciency virus (HIV) [4].hinese hamster ovary; EMA,
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Inc. This is an open access article uGiven the legacy of virus contamination with plasma-derived
FVIII products, the World Federation of Hemophilia (WFH) guide-
lines outline speciﬁc steps that help to minimise pathogen trans-
mission, which include the selection of appropriate blood or
plasma donors, the laboratory screening of raw materials (e.g.
plasma), and the elimination or removal of contaminating viruses
during product manufacture [2,3]. However, while strict quality
control measures now exist to combat the threat of blood-borne
pathogens, future infections cannot be ruled out: viruses that are
presently unknown or emerging remain a threat [5].
Recombinant FVIII (rFVIII) products are associated with a
reduced risk of transfusion-associated infections, compared with
human plasma-derived products and, following their introduction,
have become widely used [6]. However, the use of human blood
components (e.g. plasma-derived albumin) in the ﬁrst- and second-
generation rFVIII products continued to pose a risk of transmission
of blood-borne pathogens [2,6]. The development of third-
generation rFVIII products, which are free from human- and
animal-derived raw materials, represented a signiﬁcant step for-
ward in improving virus safety for haemophilia patients [7] by
eliminating risk of contamination at the raw-material sourcing
level.nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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ment and pasteurisation, and/or virus removal by separation pro-
cedures such as chromatography and nanoﬁltration, are important
contributors to product safety, for both plasma-derived and re-
combinant products. Solvent-detergent treatment is considered the
gold standard for eliminating enveloped viruses, while nano-
ﬁltration is the option of choice for removing small non-enveloped
viruses, and it can also decrease the risk of prion contamination
[8,9]. In addition, chromatographic puriﬁcation steps may also
contribute to virus clearance. At present, different FVIII products
utilise a variety of such virus removal and inactivation methods [2].
Virus contamination events rarely occur with rFVIII products
[10]. However, there are several potential sources of virus
contamination that constitute a safety risk, most frequently when
cell cultures come into contact with raw materials [10]. Besides
adventitious virus contaminants, the cell line used for manufacture
expresses endogenous retrovirus-like particles [11]. It is important,
therefore, to ensure that effective virus safety procedures are
employed throughout the manufacturing process [10]. A guideline
on evaluating the virus safety of biotechnology products derived
from cell lines of human or animal origin, i.e. ICHQ5A, has been
adopted by both the EuropeanMedicines Agency (EMA; CPMP/ICH/
295/95) [11] and United States Food and Drug Administration (FDA;
63 FR 51074) [12]. These guidelines cover three principal, comple-
mentary approaches to control the potential virus contamination of
biotechnology products: (1) selecting and testing cell lines and
other raw materials for the absence of undesirable viruses; (2)
assessing the capacity of the production processes to clear potential
human infectious viruses; and (3) testing the product at appro-
priate steps of production for the absence of contaminating infec-
tious viruses. Turoctocog alfa (NovoEight®, Novo Nordisk) is a third-
generation, B-domain-truncated rFVIII produced in the Chinese
hamster ovary (CHO) DUKX-B11 cell line, and its virus safety con-
forms to these three main control factors, as speciﬁed in the
guidelines [11,13e15].
Following the expression of turocotocog alfa in a CHO cell line,
its manufacture includes a ﬁve-step puriﬁcation process, developed
to yield a highly puriﬁed product with minimal virus contamina-
tion risk [16,17] (Fig. 1).
An anti-FVIII monoclonal antibody (mAb) immunoafﬁnity
chromatography puriﬁcation step is included. This mAb is also
produced in CHO cells without the addition of human- or animal-
derived raw materials [16,17], and the manufacturing process has
been evaluated and characterised using the same approach as in
this study. Two steps are included in the puriﬁcation process solely
for their documented effect on virus clearance: a 20-nm ﬁltration
step to remove both enveloped and non-enveloped viruses, and a
detergent washing step speciﬁcally designed to inactivate envel-
oped viruses.
A detailed explanation of the considerations behind the pro-
duction design, to ensure a robust manufacturing process that
produces a high-quality rFVIII product, is described elsewhere [17].
Here, we describe virus clearance evaluation studies that were
conducted to assess the capacity of the puriﬁcation process used in
the manufacture of turoctocog alfa to remove and/or inactivate
viruses.
2. Materials and methods
2.1. Design of virus clearance evaluation studies
Four steps in the puriﬁcation process were evaluated for the
inﬂuence of different parameters on the virus clearance capacity.
These included: (1) capture by mixed-mode chromatography using
Capto™ MCC resin (GE Healthcare Life Sciences) and a detergentwash with Triton-X 100 (Sigma Aldrich) to inactivate enveloped
viruses; (2) an immunoafﬁnity chromatography puriﬁcation step
using an anti-FVIII matrix; (3) puriﬁcation by anion-exchange
chromatography; and (4) a double nanoﬁltration step, involving
two 20-nm Planova™ 20N ﬁlters (Asahi Kasei Bioprocess; nominal
pore size 19 ± 2 nm) in series. The puriﬁcation process has been
described previously [16].
In-process materials were obtained from each step in the
production-scale process and used as starting material for virus
clearance studies. This ensures that the small scale experiment is
done with identical test material to the actual process. This ma-
terial was spiked with virus immediately prior to performing the
virus clearance evaluation. The evaluation was performed in a
scaled-down model of the manufacturing process, in facilities
designed for virus studies. In order to exclude virus aggregates,
the virus stock used for spiking was ﬁltered (minute virus of mice
[MVM], 0.1 mm; bovine enterovirus [BEV], 0.22 mm; ecotropic
murine leukaemia virus [eMuLV] and Infectious bovine rhino-
tracheitis virus [IBRV], 0.45 mm) immediately prior to use. In
accordance with current guidelines [11,13e15], a virus spike less
than 10% v/v was added to the process material, to avoid altering
the properties of the material. Separate experiments were con-
ducted for each virus individually. Holding samples were tested to
ensure that any virus clearance was due to the processing step.
Virus was analysed using textbook cell based assays detecting
infectious viruses as TCID50 or Plaque Forming Units. All process
material was tested for toxicity and to ensure non-interference,
using virus infectivity assays and appropriately diluted samples
prior to analysis. The within-assay standard deviations were as
follows: MVM, 0.21; eMuLV, 0.26; reovirus type 3 (Reo-3), 0.18;
BEV, 0.15; IBRV, 0.21, meeting the requirements deﬁned in ICHQ5A
guidelines [11].
2.2. Selection of viruses for virus clearance evaluation
The virus clearance evaluation used a broad range of virus types
e large, small, DNA, RNA, enveloped and non-enveloped viruses
(Table 1). Because the CHO production cell line produces retrovirus
like particles (RVLPs), the eMuLV was used as a model to evaluate
the puriﬁcation steps used for clearance of RVLPs and other similar
enveloped viruses, in accordance with the ICHQ5A guideline [11].
IBRV was included as a second, enveloped virus. Also included as
model viruses were: MVM, BEV and Reo-3 (Table 1). MVM and BEV
are small, non-enveloped viruses with medium to high resistance
to physical and chemical inactivation. Reo-3 is a non-enveloped,
spherical, medium-sized virus with medium resistance to physi-
cochemical inactivation.
2.3. Validity of the scaled-down manufacturing process
A scaled-down manufacturing process was used for the virus
clearance evaluations, which were conducted in accordance with
current guidelines [11,13e15]. The chromatographic steps,
including the buffer composition and resin type, were identical to
those used in the full-scale production process; ﬂow rates were also
identical on a column-volume basis, in order to maintain constant
residence times; column heights were equal to or below (worst-
case scenario) those for full-scale production. Loads (measured as
g/column volume) were at or above (worst-case scenario) those
used at full-scale. For the nanoﬁltration step, laboratory-scale ﬁlters
of the same typewere used as in production. Buffers were identical,
as were pressure, pH, volume of wash steps, ﬂux rates (per ﬁlter
area) and wash volumes (per ﬁlter area). Loads (measured per ﬁlter
area) were at or above (worst-case scenario) those used at full-scale
(Table 2).
Fig. 1. Flow diagram of turoctocog alfa manufacturing process (underlined text denotes steps in the manufacturing process evaluated for virus clearance).
Table 1
Physicochemical properties of the model viruses evaluated.
Virus Family Genome Envelope Size (nm) Resistancea
MVM Parvoviridae ssDNA No 18e24 Very high
BEV Picornaviridae ssRNA No 25e30 Medium-high
Reo-3 Reoviridae dsRNA No 60e80 Medium
IBRV Herpesviridae dsDNA Yes 145e155 Medium
eMuLV Retroviridae ssRNA Yes 80e110 Low
BEV, bovine enterovirus; eMuLV, ecotropic murine leukaemia virus; IBRV, infectious
bovine rhinotracheitis virus; MVM, minute virus of mice; Reo-3, reovirus type 3.
a Resistance to physicochemical treatments, according to the ICHQ5A guideline
[11].
Table 2
Parameters tested in the evaluations, including their associated set values and working
Puriﬁcation step Parameter
Capture by mixed-mode chromatography, including detergent
wash
pH in buffer solution
Triton contact time (
Triton concentration
Puriﬁcation by anti-FVIII matrix afﬁnity chromatography NaCl in equilibration
kg)
Length CV in replacem
Length CV in equilibr
Temperature (C)
20-nm ﬁltration pH in washing buffer
Protein concentration
Temperature (C)
CV, column volume.
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duction, used resinwas also tested for virus clearance capacity using
in-process material taken from the turoctocog alfa manufacturing
process. Reused resin for virus clearance experiments originated
from turoctocog alfa production or from laboratory-scale experi-
ments. If the resin was reused at laboratory-scale, conditions were
comparable to those for full-scale production, and new loadmaterial
from the turoctocog alfa production was used for each cycle. The
validity of the scaled-downprocess stepswas veriﬁed and conﬁrmed
by comparison of the virus clearance studies with the production
process steps (data not shown).ranges.
Set
value
Working
range
Tested value (s)
s 7.5 7.2e7.8 7.2 and 7.8
minutes) 60 60e120 45
(%) 1 0.8e1.2 0.5
and replacement buffer (mmol/ 450 150e500 120
ent step 5 0.1e10 Stable baseline (4e10
CV)
ation step 5 0.1e10 Stable baseline (4e10
CV)
20 15e25 15
and starting material 7.5 7.0e8.5 7.3 and 8.0
(g/l) 3.5 1e6 0.5 and 3.5
20 15e25 15
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Turoctocog alfa is puriﬁed in a process that includes several
dedicated virus-removal and virus-inactivation steps (Fig. 1).
Several steps in the manufacturing process have been tested for
virus clearance capacity and, depending on the puriﬁcation step,
one or more viruses evaluated. The puriﬁcation steps tested were
considered to be orthogonal, as described in the ICHQ5A guideline
[11], so a value for the overall (total) clearance achieved by the
puriﬁcation procedure was derived by evaluating the ratio of vi-
ruses before and after each puriﬁcation step and summing these
reduction factors to derive an overall value (deﬁned as log10 of the
summed reduction factors). Determinations were performed in
duplicate and average values derived for reduction factors.
Turoctocog alfa-expressing CHO cells are propagated from the
working cell bank, which is inoculated into shaker ﬂasks and
expanded. The expanded culture is used to inoculate the ﬁrst
propagation bioreactor, and is further expanded in propagation
bioreactors until a sufﬁcient cell number is obtained for inoculation
of the large-scale production bioreactor. The product is then sterile
ﬁltered. The main cell culture operates as a draw-ﬁll cultivation
process, with a harvest interval of 3 days. Each harvest of culture
liquid is clariﬁed by a sequence of centrifugation and ﬁltration
before capture and puriﬁcation. The product is concentrated in the
capture step, using mixed-mode chromatography (a detergent
wash is included in this step). The puriﬁcation process continues
with a reduction in the presence of product-related impurities and
host cell protein (HCP) using immunoafﬁnity chromatography with
a monoclonal antibody (mAb) against the heavy chain of FVIII. This
is followed by an anion-exchange chromatographic step, which
concentrates the product and further reduces HCP and mAb
leakage. Subsequently, the product is passed through a 20-nm ﬁlter
in a virus ﬁltration step before the ﬁnal step in the puriﬁcation
process of buffer exchange and size-exclusion chromatography.
This step reduces high molecular weight proteins, reduces HCP and
exchanges the buffer for the ﬁnal buffer. The product is then
ﬁltered, dispensed into containers and stored at a temperature
below 70 C.
3. Results
Four steps in the virus puriﬁcation process were evaluated for
their virus clearance capacity. These included: (1) capture by
mixed-mode chromatography, including a detergent wash to
inactivate enveloped viruses; (2) afﬁnity chromatography puriﬁ-
cation using an anti FVIII matrix; (3) puriﬁcation by anion-
exchange chromatography; and (4) 20-nm ﬁltration.
3.1. Capture by mixed mode chromatography and detergent wash
In the ﬁrst puriﬁcation process step, which utilises the Capto
MMC resin and includes a dedicated virus inactivation step via a
detergent washwith Triton X-100, turoctocog alfa binds to the resin
and, while bound, the resin is washed with detergent for at least
60 min (60e120 min). Subsequently, the detergent is washed out
and the product is eluted in a buffer without detergent. Of the ﬁve
viruses tested, the enveloped viruses, eMuLV and IBRV, were
cleared completely (i.e. no recovery of infectious virus), with
reduction factors of >7.8 log10 and >6.3 log10, respectively (Table 3).
This step also contributed to clearance of BEV, Reo-3, and MVM,
though to a lesser extent. Within the pH range and temperatures
speciﬁed in the manufacturing process, no difference was seen in
virus clearance. With regard to the effect of reusing the chro-
matographic matrix, the repeated use of resin did not adversely
affect virus clearance studies (Table 4). None of the viruses testedbound to the column, as virus nucleic acid, detected by PCR, was in
the ﬂow-through fraction (data not shown).
The clearance values given are based on duplicate de-
terminations. Since SD estimates based on only duplicate de-
terminations are not reliable, no estimate of SD for the LRV are
provided. BEV, bovine enterovirus; eMuLV, ecotropic murine
leukaemia virus; IBRV, infectious bovine rhinotracheitis virus; LRV,
log10 reduction value; MMC, multimode chromatography; MVM,
minute virus of mice; Reo-3, reovirus type 3.
The clearance values given are based on duplicate de-
terminations. Since SD estimates based on only duplicate de-
terminations are not reliable, no estimate of SD for the LRV are
provided. BEV, bovine enterovirus; eMuLV, ecotropic murine
leukaemia virus; IBRV, infectious bovine rhinotracheitis virus; LRV,
log10 reduction value; MMC, multimode chromatography; MVM,
minute virus of mice; Reo-3, reovirus type 3.
3.2. Puriﬁcation by anti-FVIII matrix
This step involves immunoafﬁnity chromatography, using the
anti-FVIII matrix, which has been previously characterised [18].
This step effectively cleared both eMuLV and BEV viruses and also
contributed to the clearance of Reo and MVM (Table 3).
Evaluation of the inﬂuence of different parameters used in this
step was performed using MVM, Reo-3 and BEV (Table 4). Variation
of salt concentration and temperature (within, or just outside,
production limits) or repeated use of the anti-FVIII matrix did not
adversely affect virus clearance (Tables 3 and 4). None of the viruses
tested bound to the column to a signiﬁcant extent, as virus nucleic
acid, detected by PCR, was mainly detected in the ﬂow-through
fraction (data not shown).
3.3. Puriﬁcation by anion-exchange chromatography
The primary aim of this step is to remove protein impurities.
Anion-exchange chromatography, performed using MVM, achieved
a reduction factor of 1.3 log10, demonstrating that it provides an
additional, though modest virus removal of non-enveloped viruses
(Table 2). Virus appeared strongly bound to the column, as virus
nucleic acid, detected by PCR, was not found in ﬂow-through, wash
or eluate fractions (data not shown).
3.4. 20-nm ﬁltration
Turoctocog alfa is ﬁltered by using two 20-nm (double 20-nm)
ﬁlters in series; that is to say two Planova 20N ﬁlters in series. In
order to mimic the manufacturing process, the pressure was
released after ﬁltration and buffer was used to wash the ﬁlter. The
same amount of buffer per ﬁlter area was used as deﬁned for the
manufacturing process. All viruses used in this stepwere effectively
and robustly cleared (reduction factor >4 log10). The size of the
virus particle is a critical factor in determining virus clearance ca-
pacity of the 20-nm virus ﬁlter. MVM is 18e24 nm in diameter,
which is within the same range as the nominal pore size
(19 ± 2 nm) of the ﬁlter. In the case of BEV e the second model
virus, chosen to further challenge the virus ﬁltration method
because of its larger size (25e30 nm) e clearance was higher than
that of MVM (Table 2), as anticipated. The ﬁltration step was
evaluated only for the smaller viruses, MVM and BEV, and not for
Reo-3, as this constituted a more robust test of ﬁltration
effectiveness.
The inﬂuence of different parameters was evaluated using
MVM.Within the pH range and temperature tested, virus clearance
was the same as that achieved in the tests performed at set
manufacturing points (data not shown). At values below pH 7.3, or
Table 3
Virus clearance evaluation: results with new resin.
Description Reduction factor, log10
eMuLV MVM Reo-3 BEV IBRV
Capture Capto MMC, incl. 60-min Triton X-100 wash >7.8a 1.2 2.9 3.3 >6.3
Anti-FVIII matrix afﬁnity chromatography >4.9 2.0 3.9 4.6 Not evaluated
Poros 50 HQ anion-exchange chromatography Not evaluated 1.3 Not evaluated Not evaluated Not evaluated
Planova 20N virus reduction ﬁltration 5.3c 6.5 69. Not evaluated >7.4 >6.4c
Total clearance >18.0 11.0 >6.8b >15.3 >12.7
a eMuLV was inactivated after 15 min, or after <45 min at room temperature.
b Contribution from the virus ﬁltration was not evaluated, but the reduction factor was conservatively estimated at >5.0 log10, ensuring a cumulative clearance of well above
10 log10 (the smaller virus, i.e. MVM value, is used for calculating overall clearance).
c Due to their large size, effective clearance was expected and only one ﬁlter was used in these studies. Actual values will be higher in themanufacturing scale process due to
the use of 2 ﬁlters in series.
Table 4
Virus clearance evaluation: results with reused resin.
Description Times resin used Reduction factor, log10
eMuLV MVM Reo-3 BEV IBRV
Capture Capto MMC, incl. 60-min Triton X-100 wash 41 >5.6a 1.9 3.9 4.2 >6.8
Anti-FVIII matrix afﬁnity chromatography 51 Not evaluated 1.1 3.8 4.2 Not evaluated
Poros 50 HQ anion- exchange chromatography 16 Not evaluated 1.0 Not evaluated Not evaluated Not evaluated
a Due to differences in the virus titre in the spike used in the evaluation, it was not possible to demonstrate reduction factors that were comparable to those observed in tests
with new resin. However, in both evaluations, complete clearance of virus was observed.
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after only 5e10 kg/m2 had been ﬁltered.
The virus reduction result obtained for eMuLV in the virus
ﬁltration step was surprising, and may underestimate the actual
effect of the nanoﬁlter, based on two factors. Firstly, the value re-
ported represents the average of two determinations. In the ﬁrst
experiment, no eMuLV was recovered post-ﬁltration, correspond-
ing to log10 reduction value (LRV) > 5.1. In the second experiment,
one plaque was observed during large-volume virus assay on
ﬁltrate, giving a LRV of 5.5. Due to the large size of eMuLV it is
unlikely that the plaque is due to a virus having penetrated the
ﬁlter, but instead, is more likely due to cross contamination of
ﬁltrate. During the experiment, concentrated virus is handled in
close proximity to the ﬁltration (segregation as applied in
manufacturing facility not used in virus study) and, due to open
handling, we cannot rule out the possibility of aerosol contami-
nation of the experiment. Since this is a theoretical consideration,
we could not justify disregarding the result and repeating the
determination. It would, however be surprising if virus retention of
a large virus such as eMuLV is lower than that observed with a
much smaller virus such as BEV. The second factor to consider is
that the virus clearance with eMuLV was performed using one ﬁlter
only. In large-scale production, two ﬁlters (in series) are used.
Assuming the same clearance on the second ﬁlter would not be
justiﬁed, but completely disregarding an effect of this second ﬁlter
would also be misleading.3.5. Overall virus clearance evaluation using eMuLV, IBRV, MVM,
Reo-3 and BEV
The different manufacturing steps evaluated e responsible for
virus inactivation/removal e are based on different mechanisms. In
consequence, the virus reduction factors of the individual steps of
turoctocog alfa puriﬁcation may, therefore, be added to provide an
estimate of the overall virus clearance of the entire process
(reduction factor deﬁned as log10 of the ratio of virus pre- and post-
puriﬁcation). The overall virus clearance, in terms of reduction
factors were: >18.0 log10 for eMuLV; 11.0 log10 for MVM; >11.8 log10for Reo-3 (including an estimated reduction of >5.0 log10);
>15.3 log10 for BEV; and >12.7 log10 for IBRV. Where investigated,
the same virus clearance was achieved with reused resins (Table 3).
As in the overall puriﬁcation process, all ﬁve viruses were cleared
effectively (Table 3).
The clearance values given are based on duplicate de-
terminations. Since standard deviation (SD) estimates based on
only duplicate determinations are not reliable, no estimate of SD for
the LRV are given in Tables 2 and 3 Different factors contribute to
the SD of the LRV; most notably (but not solely) the SD of the virus
titration assays used. These have SD ranging from 0.15 to 0.26 (log10
[titer]) (see Section 2.1), in accordance with the requirement set
forth in ICHQ5A guidelines [11]. The contribution to SD for LRV will
be from 0.21 to 0.37, or, in terms of conﬁdence interval (2  SD),
0.42 to 0.74.4. Discussion
The ICHQ5A(R1) guideline establishes a framework for ensuring
the virus safety of biotechnological medicinal products, and this
guideline has been adopted by both US [12] and European regula-
tory agencies [11]. Virus safety is assured only by a combination of
different measures, one of which is the virus removal capacity of
the manufacturing process. Another measure is testing for absence
of contaminating infectious viruses at appropriate steps of pro-
duction [11].
Turoctocog alfa is a third-generation rFVIII product, produced
from a CHO cell line expressing a B-domain-truncated form of
human FVIII. After its expression in bioreactors, the rFVIII molecule
is puriﬁed through a series of steps designed to ensure virus safety
early on in the manufacturing process. These include solvent-
detergent inactivation with Triton X-100, puriﬁcation column
chromatography steps, and double 20-nm ﬁltration with two Pla-
nova 20N ﬁlters in series [17].
In producing any biopharmaceutical products, manufacturing
parameters that may inﬂuence puriﬁcation should be properly
deﬁned and controlled [11]. Furthermore, if multiple virus safety
steps are employed, the contribution of these as a whole should be
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dividual puriﬁcation steps used in the manufacture of turoctocog
alfa to remove or inactivate eMuLV, MVM, Reo-3, BEV and IBRV
were assessed. This analysis revealed overall virus reduction factors
ranging from >5.0 log10 to >18.0 log10. These values are comparable
towhat others have observed for similar processes, such as work by
Casademunt et al. [19].
With regard to the individual puriﬁcation steps, capture by
mixed-mode chromatography, including a detergent wash,
completely inactivated the enveloped viruses eMuLV and IBRV, as
expected. This is consistent with the capability of Triton X-100 as a
highly efﬁcient in activator of enveloped viruses, due to its
disruption of virus lipid bilayer membranes.
The salt wash associated with the afﬁnity chromatography step
was expected to provide additional virus clearance. However, as
viruses have different charges and proteins on their surfaces, and
can thus bind to chromatography columns differently, it is difﬁcult
to predict which types of virus will be effectively removed. This
study demonstrated that chromatography columns effectively
cleared both eMuLV and BEV viruses.
At present, turoctocog alfa is the only rFVIII molecule to be
manufactured using double 20-nm ﬁltration, to maximise the
robustness of the puriﬁcation process. This ﬁlter pore size was
chosen because the large majority of viruses have dimensions that
lie within 20e250 nm [20]. Nevertheless, ﬂux characteristics
through the ﬁlters is also an important consideration. The size of
the virus particle is a critical factor in determining virus clearance
capacity of the 20-nm virus ﬁlter. MVM, a virus that is 18e24 nm in
diameter [11], and therefore comparable in size to the nominal pore
size (19 ± 2 nm) of the ﬁlter, was successfully cleared, independent
of the pH conditions. The successful clearance of BEV is further
evidence of the efﬁcacy of the nanoﬁltration system.
Studies of robustness are important to determine whether mi-
nor variations in process parameters are critical and, if so, to deﬁne
limits towhich themanufacturing process should adhere, to ensure
sufﬁcient virus clearance capacity. In this study, virus clearancewas
investigated using worst-case conditions wherever possible; when
such conditions could not be determined, the capacity of the pu-
riﬁcation step was evaluated at both ends of the working ranges for
most parameters. Taken together, these ﬁndings conﬁrm that the
manufacturing process for turoctocog alfa effectively removes a
range of enveloped and non-enveloped viruses of different sizes.
Furthermore, no difference was observed between new and reused
resins, demonstrating that virus clearance is robust, with respect to
the need for the repeated use of resins in manufacturing runs.
In summary, this study has validated the turoctocog alfa puri-
ﬁcation process, showing that it is highly effective and robust, in
terms of the inactivation and removal of both enveloped and non-
enveloped viruses. The absence of infectious contaminating virus in
unprocessed bulk harvest was investigated by an in vitro assay
testing each batch for adventitious viruses (data not shown). If trace
amounts of virus (below limit of detection) were not detected in
this assay, they would have been effectively removed by the virus
clearance capacity of the puriﬁcation process.
The use of multiple virus safety techniques in the manufacture
of turoctocog alfa is based on sound scientiﬁc principles, and the
high overall virus safety of this new recombinant FVIII product has
been achieved by closely integrating virus clearancewith the entire
manufacturing process.
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